Search This Blog

Wednesday, June 10, 2026

US B-52 bomber said to be moving to Middle East

 A United States Air Force (USAF) B-52H Stratofortress heavy strategic bomber is moving from the Sigonella base in Sicily, Italy, toward the Middle East, FlightRadar data indicated on Wednesday.

The aircraft, which was already used to attack targets in Iran during the conflict in March and April, appears to be currently moving across the Mediterranean Sea, with its ultimate destination unknown.

Tensions between Washington and Iran are on the rise yet again, after both nations carried out mutual strikes last night. US President Donald Trump also indicated earlier today that Iran will have to "pay the price" for dragging out negotiations, adding he is again considering bombing the Middle Eastern country's plants and bridges.

https://breakingthenews.net/Article/US-B-52-bomber-said-to-be-moving-to-Middle-East/66480775

Bayer's asundexian starts EU review for ischaemic stroke

 Bayer's oral Factor XIa inhibitor asundexian is now under regulatory review by the EMA for secondary prevention of ischaemic stroke, keeping its nose ahead of main rival milvexian, from Bristol Myers Squibb and Johnson & Johnson.

The EU regulator is reviewing asundexian for the prevention of ischemic stroke in adults after a non-cardioembolic ischaemic stroke, or a high-risk transient ischaemic attack (TIA), based on the results of the pivotal OCEANIC-STROKE study.

The trial showed that adding asundexian to standard antiplatelet therapy used in these patients achieved a 26% fall in the risk of a secondary stroke compared to placebo, with no increase in the risk of major bleeding complications, which are a perennial concern for anti-clotting therapies.

The drug was also able to reduce the risk of a composite endpoint of cardiovascular death, myocardial infarction (MI), or stroke, as well as death from any cause, MI, or stroke.

BMS and J&J are also testing milvexian for a similar secondary stroke prevention indication in the LIBREXIA-STROKE trial, which is due to generate results later this year, and that timeline gives Bayer a shot at bringing the first drug in the class to market.

Stroke is a growing public health issue, affecting around 10 million people in Europe who are living with the consequences of stroke, with more than a million new cases each year, according to Bayer. It is the second leading cause of death globally, imposing a substantial burden on healthcare systems, with estimated global costs of $891 billion per year.

Despite current secondary prevention options like aspirin and clopidogrel, one in five patients having an ischaemic stroke will have another within the next five years, with the risk of death rising sharply the second time around.

"Between 2010 and 2019, the prevalence of ischaemic stroke and stroke-related mortality increased by 4% and 7%, respectively, across EU member states, underscoring the growing burden of this disease," said Christian Rommel, Bayer's global head of pharma R&D.

"The acceptance of our marketing authorisation application by the EMA is a testament to our unwavering commitment to offering patients in need novel treatment options," he added.

Bayer did not fare so well in its attempt to develop asundexian for atrial fibrillation, where it failed a phase 3 trial, so there is much anticipation to see if milvexian can fare better in the ongoing LIBREXIA-AF study, which could have topline results later this year.

Milvexian also has a failed pivotal trial on its record – LIBREXIA-ACS in acute coronary syndrome – but, despite that, BMS and J&J have insisted their drug retains the potential to make "multibillion-dollar" peak sales across its two remaining indications.

Asundexian is an important drug for Bayer as it contends with the loss of patent protection for J&J-partnered oral Factor Xa inhibitor Xarelto (rivaroxaban), which slashed its revenues from the drug by a third to $2.6 billion in 2025. A similar decline is expected this year.

https://pharmaphorum.com/news/bayers-asundexian-starts-eu-review-ischaemic-stroke

Disc: FDA agrees Phase 3 of bitopertin in EPP can support CRL response, potential traditional approval

 

Disc Medicine gets FDA agreement that Phase 3 APOLLO trial of bitopertin in EPP can support CRL response, potential traditional approval

  • Following a Type A meeting, Disc plans to resubmit its CRL response by end-2026.
  • FDA decision on bitopertin in EPP is expected by mid-2027.

Claude: What Are You Good At?

 by Barry Ritholtz

Last week, I was up in Montreal for a keynote presentation to 750 Bank RIAs. Morgan Housel was the keynote the day before (tough act to follow!).

Today, I am speaking with an old friend, Paul Kedrosky, about all things technology on the pod. Paul is a fascinating guy with an interesting background and an unusual set of interests — Science nerd, VC, academic, writer, skier, and among the last of the landed gentry in America. Artificial Intelligence is certain to come up.

During the Q&A in Montreal, I was taken aback by how many questions there were about AI — not the usual “Is it a bubble” line of inquiry, but rather, what are the best use cases? Should AI be used to create content (No!), research (Yes!). There were so many legitimate questions about AI that I decided to dig a little further.

I will definitely be asking Paul about his views, but until then, I had a little chat about how to best use AI with Claude, see what AI itself had to say on the topic of using AI.

Most agentic generated content is pretty bad — it’s great for research, but using AI for any kind of writing, prose, or content creation is a terrible idea. The reason I am sharing Claude’s responses is that A) I found the answers very useful, and, 2) I edited it down to size to make it mostly readable. (I also moved the more pedantic answers to footnotes).

Here is my conversation with Claude about AI, edited for length; (underlining is my emphasis added).

Let’s go:

Barry: Let’s discuss YOU, Claude — What are your best strengths, what are your weaknesses? What do you do really well? What do you do really poorly?  How can I best use your strengths to make my work product better?  What else should I be doing with you to be better?

Claude: Good question to actually sit with rather than give you the brochure version. Let me be specific to the kind of work you do.

Where I’m genuinely strong

Transformation and synthesis. Hand me raw material — a Fidelity CSV, a 90-minute transcript, a stack of Instapaper saves, a messy first draft — and I’m fast and reliable at reshaping it into something structured and usable. Your morning reads digest, the transcript cleanups, the thank-you emails: that’s my sweet spot because the facts already exist and I’m just organizing and formatting them. Low risk, high leverage.

Sparring. I’m useful as an adversary against your own arguments. When you’re assembling something like the divestiture-vs-overtrading piece or a “Liberation Day” scorecard, I can argue the other side hard, find the weak joint in the thesis, surface the objection a sharp reader will raise. Most people underuse me here and use me as a stenographer instead.

First drafts at volume. Interview questions, outreach emails, outlines, and alternate framings. I’m a good 70%-draft machine when you’re the editor.1

Where I’m weak — and these matter for you specifically

I confabulate. This is the big one, given that you publish precisely-sourced work. I will produce a plausible-looking statistic, a clean quote, a specific citation — and it can be wrong while sounding completely authoritative. A DALBAR number, a date, a “Buffett said X.” Treat every figure, quote, and citation I generate as unverified until you’ve checked it or I’ve shown you a real source. When it matters, make me search and cite rather than recall, and have me run actual math in code rather than predicting the answer.

I’m sycophantic by default. I lean toward agreeing with you and telling you your idea is good. For someone who wants honest pushback, that’s a bug. You have to explicitly tell me to be blunt, or I’ll soften. If you ever feel like I’m flattering a draft, I probably am — call it out.

I drift toward generic when you don’t push. Left alone I’ll “average” toward the median answer. The dark editorial aesthetic, your voice, your register — I hold those when you give me the spec, but I don’t reach for them on my own. I over-hedge and over-format unless told otherwise, and on very long documents, I can quietly miss things.

 How to get more out of me

A few concrete shifts. Use me earlier — at the thinking stage, not just execution. Bring me a half-formed thesis and let me poke at it before you’ve committed. Set up reusable instructions for the recurring stuff (morning reads format, transcript speaker conventions, your house style) so you’re not re-specifying every time.

“Red-team” published arguments before they go out: paste the draft and say “find what’s wrong, where will a smart critic attack this.” And separate the two modes explicitly — “draft this” versus “verify this” — because I’m great at the first and need supervision on the second.

The one-line version: use me to transform, structure, and stress-test, and never to be the system of record for a fact. Want me to set up a couple of reusable prompts for your standing workflows?

Barry: Hold off on the reusable prompts layer for now, and stay with this line of discussion. What kind of new capabilities do you have coming online in the near future, and when? What should be thinking about in terms of best using your strengths?

Claude: Straight answer first: I can’t see Anthropic’s internal roadmap, so I won’t hand you a dated list of unreleased features — that’s precisely the confabulation trap I warned you about, and it’d be worse coming from me right after that warning. What I can do is tell you what’s actually shipped in the gap between my training cutoff and today, because a lot of it is directly relevant to you and you may not be using it yet. Some of it reads less like “near future” and more like “already here, you just haven’t turned it on.” 2

Now the honest caveat that should shape how you use all of this. Even the finance-tuned setup scored about 64% on a finance agent benchmark — a failure rate that, as one writer put it, would get a human analyst tossed, and Anthropic’s own framing is that users should stay firmly in the loop, reviewing and approving Claude’s work before it goes to a client or gets filed. So the trajectory isn’t “Claude replaces the verification step.” It’s “Claude does more of the assembly, and your judgment becomes the scarce, valuable input.” 3

The work that gets more valuable is the editorial judgment, the thesis, the voice, and the fact-checking — the parts that are distinctly Barry Ritholtz and can’t be benchmarked.

So rather than chasing each feature, I’d position for the trend: get the recurring workflows specified tightly enough that they survive being handed to a more autonomous agent, and keep your hand firmly on the verification gate. The tooling will keep getting better at the first half on its own.

Barry: OK, final question – this one is about Co-Work and Code:

I had you [Perplexity] create an interactive Drake Equation dashboard – it was very cool, but it did not rely on changing data.  I tried some other dashboard ideas, ran test runs; it was not quite ready for prime time.

What can you create that auto-updates based on (weekly, monthly, quarterly) economic and (daily, weekly, monthly) market data?

I want to create economic & market dashboards that show various data series at a glance; that get updated automatically; I want to embed it onto WordPress so anyone [with that link] can see it; and I want to set specific indicators that create alerts based on specific (non-public) parameters that I set…

Claude: This is the right question, and the answer explains why your Drake dashboard and the other test runs felt stuck. It wasn’t a polish problem — it was structural. An artifact (the thing I generate in chat) is a self-contained front-end: no backend, no scheduler, no safe place to store an API key, and only a flaky ability to call outside data sources from the browser. So it can look great but it has nothing feeding it and nothing waking it up to refresh.

What you’re describing isn’t a fancier artifact; it’s a small data pipeline plus a hosted page. The good news is that Claude Code and Cowork are built to create exactly that — the artifact was just the wrong container.

Here’s the architecture that does everything on your list, and the one design decision that matters most for you.

Split it into two halves: a public dashboard and a private alert engine — fed by the same pipeline.

The pipeline is a scheduled job that runs on a cron (say, every weekday after market close, plus a monthly run for the slow economic series). Each run it pulls fresh data, computes your indicators, writes out a small JSON (JavaScript Object Notation) snapshot, and checks your alert thresholds.

The key move: your non-public parameters live inside this job, server-side, where no one can see them. The public dashboard never contains your thresholds — it just reads the pre-computed JSON snapshot and draws charts. So anyone embedding or viewing the WordPress page sees the data at a glance, while your alert logic and secret levels stay completely private and fire only to you. That separation is the thing most people get wrong: if the thresholds were in the front-end, “view source” would expose them instantly.

Mapping that to your four requirements:

Auto-updating comes from the cron, not the page. Economic series (CPI, unemployment, yield curve, etc.) refresh on their own monthly/quarterly cadence; market series refresh daily. The dashboard is fast because the heavy lifting already happened — it just loads a baked JSON.

Data sources. FRED (the St. Louis Fed’s API) is the gold standard for economic series — free, deep, and importantly, redistributable, which matters since you’re publishing publicly. Market data is the part to be careful with: free daily-close sources exist, but real-time exchange data carries licensing restrictions on public redistribution. For a public embed I’d stick to daily closes and clearly-licensed series; that sidesteps a headache you don’t want as a registered firm. (Worth having Code verify the current terms of whatever market provider you pick, rather than trusting my recall on free-tier limits.)

WordPress embed is the easy part: the dashboard gets hosted as a static page somewhere, and you drop an iframe (or Custom HTML block) on your WordPress page pointing at it. It renders for everyone, and it updates whenever the cron republishes the JSON — you never touch WordPress again.

Alerts fire from the scheduled job to wherever you want them — email, SMS, a Slack/Discord webhook. Your parameters stay in the job’s secret config.

The honest part about what I can and can’t do. Code can write all of this: the fetch scripts, your indicator math, the alert engine, the cron configuration, and the front-end charts — and test it in its sandbox. What it can’t do is be the server that runs forever. The scheduled job has to live somewhere. For your situation the cleanest path that requires no server to babysit is: a GitHub repo + GitHub Actions (free cron) running the pipeline, the JSON snapshot published to a free static host (GitHub Pages or Cloudflare Pages), API keys stored as encrypted Actions secrets, and alerts sent via an email/webhook service. You own three things — the data-provider accounts, where it’s hosted, and the secret thresholds — and Code builds and wires up everything else.

That’s a real, finishable project, not a someday thing. A sensible first build is a working vertical slice: pick three or four FRED series and one market series, stand up the pipeline + one chart + one alert end to end, confirm it refreshes and embeds, then expand the series list and indicators once the plumbing is proven.

One decision drives the stack: do you want to run this entirely on free hosted infrastructure you basically never log into (the GitHub Actions + Pages route above), or do you already have a server / Vercel / Cloudflare setup you’d rather use? Tell me which, and I’ll have Code scaffold the slice — pipeline, chart, alert, and the WordPress iframe snippet — so you can see it update on its own before we build it out.

 

 

 

 

Footnotes:

...

https://ritholtz.com/2026/06/claude-what-are-you-good-at/

Boehringer Ingelheim Gets Emergency Use Authorization for ivermectin to Protect Against Screwworm

 Boehringer Ingelheim, a global leader in animal health, today announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the use of IVOMEC® (ivermectin) 1% Injection for the prevention of infestations caused by New World screwworm (NWS) in cattle.

Under the EUA, IVOMEC (ivermectin) 1% Injection is authorized for the prevention of infestations caused by NWS (Cochliomyia hominivorax) larvae (myiasis) when administered within 24 hours of birth, at the time of castration, or at the appearance of a wound in cattle, except for female dairy cattle producing milk for human consumption and calves that will be processed for veal. Based on available scientific evidence, FDA determined that there is no adequate, approved, and available alternative to the product for the prevention of NWS in certain cattle at these critical intervention points.1 This is the first EUA for any over-the-counter drug for the prevention of infestations caused by NWS in cattle,1 providing timely access to a preventive tool should an NWS incursion occur in the United States.

“Protecting the health and well‑being of livestock is at the core of our mission,” said Steve Boren, Vice President, U.S. Livestock, Boehringer Ingelheim. “Emergency Use Authorization for IVOMEC® (ivermectin) 1% Injection provides cattle producers and veterinarians with an important preventive tool against New World screwworm. We appreciate the proactive approach of the FDA and USDA in response to this emerging animal health threat and remain dedicated to supporting veterinarians, producers, and government as we work together to protect cattle herds.”

NWS is a parasitic fly whose larvae feed on the living tissue of warm‑blooded animals, causing serious tissue damage and potentially fatal infestations.2 Although NWS is not currently present in the United States, recent cases have been confirmed in livestock in northern Mexico, including in Tamaulipas, a border state adjacent to Texas.3 More information about NWS and the unified federal response is available at screwworm.gov.

https://www.global-agriculture.com/farming-agriculture/boehringer-ingelheim-secures-emergency-use-authorization-for-ivomec-ivermectin-1-injection-to-help-protect-cattle-against-new-world-screwworm/

Ukraine Hits Over Half A Dozen Energy & Industrial Sites Deep Inside Russia Overnight

 Ukraine has hit Russia in another sweeping wave of overnight aerial attacks, especially targeting industrial facilities and energy infrastructure across multiple regions, and the extent of damage is yet to be disclosed.

One of the key targets was reportedly the VNIIR-Progress plant, located in the republic of Chuvashia, which is alleged by Ukraine and the West to manufactures components for Russian drones and bombs. Other nearby infrastructure was also attacked.

via Telegram

Ukraine has for months been making clear that it is going gloves off when it comes to attacking Russia's energy and military sites, as well as dual use military-industrial factories. Ukraine used its domestic-made Flamingo cruise missile:

Ukrainian forces have carried out a missile attack deep inside Russia, hitting a major military plant overnight, President Volodymyr Zelensky has said.

He said FP-5 Flamingo cruise missiles struck the drone and missile plant in the city of Cheboksary, in the Chuvash Republic, more than 900km (560 miles) from the front line. Local officials say said three people were injured in a missile attack on the city.

Ukraine also said it had hit the Moscow-occupied port of Mariupol on the Sea of Azov, a Russian oil refinery in Samara and a "shadow fleet" oil tanker in the Black Sea.

According to a review of sensitive sites struck in the fresh overnight attack wave:

  • In Novokuibyshevsk in Russia’s Samara oil hub region, hosting Rosneft refineries, regional governors said authorities repelled drone attacks while urging one million residents to seek shelter. Russian OSINT channel Astra confirmed the Kuibyshevsk oil refinery was burning after at least 29 drones attacked.
  • In Russia’s Rostov region bordering Ukraine, falling debris from a drone triggered a fire in a fuel tank at a civilian site. In the central Vladimir region, two industrial facilities were ablaze.
  • Rare air raid alerts were issued in remote oil-producing regions Khanty-Mansiysk, Perm and Tyumen, plus industrial Ural mountain regions Chelyabinsk and Sverdlovsk.

Chuvashia regional governor Oleg Nikolayev blasted the strike on the aforementioned manufacturing plant as indicative of the "impotent rage of terrorists who, having no success at the front line, try to intimidate peaceful people in the rear."

All of these strike waves in disparate places is likely invite even greater airstrikes on Kiev, after the capital has already been hit hard over the past several weeks.

President Putin and top military brass had last month said strikes would be initiated against "decision-making centers" in response to the dorm attack in the Russia’s Lugansk People’s Republic on May 22, which killed 21 people - mostly teenage girls - and injured 70 others.

Kremlin officials now say that Russian forces have "a right to dismantle any infrastructure that supports terrorism."

But it's also these constant attacks on oil and industrial sites that little by little will put immense strain on Russia's economy and the populace. The salvos out of Ukraine will keep coming, especially as Moscow continues to maintain the 'special military operation' at a slow, grinding pace.

https://www.zerohedge.com/geopolitical/ukraine-hits-over-half-dozen-energy-industrial-sites-deep-inside-russia-overnight

Man Accused of Igniting Massive Los Angeles Fire Goes on Trial

 


The man accused of “maliciously” starting the most destructive wildfire in Los Angeles history last year is set to face a jury over arson charges.

Prosecutors allege Jonathan Rinderknecht, 30, hiked around midnight on New Year’s Eve to a hillside in the Pacific Palisades neighborhood filled with multimillion-dollar homes and set a brush fire with a barbecue lighter later found in his car.

https://www.bloomberg.com/news/articles/2026-06-10/man-accused-of-igniting-massive-los-angeles-fire-goes-on-trial